Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)

NCT04378010 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

NCT NCT04378010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04378010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Terminated
Start date
January 27, 2020
Completion date
November 30, 2021
Enrollment
98 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis